MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Myomo Retained Earnings 2011-2026 | MYO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Myomo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -88.8 M | -78.1 M | -67.7 M | -56.1 M | -45.3 M | -35 M | -22.9 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.9 M | -88.8 M | -56.3 M |
Quarterly Retained Earnings Myomo
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -115 M | -111 M | -107 M | -103 M | -103 M | -102 M | -101 M | -96.9 M | -94.5 M | -92.4 M | -91.4 M | -88.8 M | -86.6 M | - | -80.9 M | -78.1 M | -75.3 M | -73.3 M | -70.7 M | -67.7 M | -67.7 M | -67.7 M | -67.7 M | -56.1 M | -56.1 M | -56.1 M | -56.1 M | -45.3 M | -45.3 M | -45.3 M | -45.3 M | -35 M | -35 M | -35 M | -35 M | -22.9 M | -22.9 M | -22.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -22.9 M | -115 M | -69.1 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M |  USA |
 |
AxoGen
AXGN
|
-291 M | $ 32.61 | -3.81 % | $ 1.44 B | USA |
 |
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | USA |
 |
Acutus Medical
AFIB
|
-600 M | - | -26.83 % | $ 2.62 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | USA |
 |
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
-54.4 M | $ 3.82 | -2.55 % | $ 132 M | USA |
 |
Alphatec Holdings
ATEC
|
-1.28 B | $ 13.1 | -2.75 % | $ 1.87 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-157 M | $ 6.87 | -4.58 % | $ 493 M |  Israel |
 |
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | USA |
 |
Bio-Rad Laboratories
BIO
|
7.42 B | $ 292.42 | - | $ 8.25 B | USA |
 |
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
2.41 B | $ 37.51 | -11.6 % | $ 5.59 K | USA |
 |
BioSig Technologies
BSGM
|
-255 M | - | 37.08 % | $ 85.7 M | USA |
 |
CONMED Corporation
CNMD
|
560 M | $ 41.67 | - | $ 1.29 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.67 B | $ 74.12 | - | $ 109 B | USA |
 |
Abbott Laboratories
ABT
|
47.3 B | $ 111.47 | -1.87 % | $ 194 B | USA |
 |
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | USA |
 |
ClearPoint Neuro
CLPT
|
-191 M | $ 13.04 | -2.47 % | $ 352 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 4.77 | -2.65 % | $ 178 M |  France |
 |
Electromed
ELMD
|
21.2 M | $ 23.31 | - | $ 197 M | USA |
 |
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-395 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | USA |
 |
Eargo
EAR
|
-514 M | - | - | $ 10.2 M | USA |
 |
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | USA |
 |
Second Sight Medical Products
EYES
|
-122 M | - | -0.97 % | $ 54.4 M | USA |
 |
InMode Ltd.
INMD
|
875 M | $ 14.3 | 0.42 % | $ 1.13 B | Israel |
 |
IRadimed Corporation
IRMD
|
56.8 M | $ 99.84 | -3.14 % | $ 1.26 B | USA |
 |
Integer Holdings Corporation
ITGR
|
891 M | $ 85.36 | - | $ 2.87 B | USA |
 |
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
-33.6 M | $ 18.54 | -0.22 % | $ 122 M | USA |
 |
Globus Medical
GMED
|
1.15 B | $ 87.22 | - | $ 11.8 B | USA |
 |
Pulmonx Corporation
LUNG
|
-468 M | $ 1.42 | -2.07 % | $ 55.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
940 M | $ 10.81 | -3.31 % | $ 832 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-445 M | $ 73.54 | 1.13 % | $ 2.07 B |  Costa-rica |
 |
IRIDEX Corporation
IRIX
|
-79 M | $ 1.38 | -3.5 % | $ 22.3 M | USA |
 |
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-304 M | $ 0.64 | 2.39 % | $ 34.8 M | USA |